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ABSTRACT
Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME) is an acquired,
complex and multisystem condition of unknown etiology, no established diagnostic lab tests and
no universally FDA-approved drugs for treatment. CFS/ME is characterised by unexplicable dis-
abling fatigue and is often also associated with numerous core symptoms. A growing body of
evidence suggests that extracellular vesicles (EVs) play a role in cell-to-cell communication, and are
involved in both physiological and pathological processes. To date, no data on EV biology in CFS/
ME are as yet available. The aim of this study was to isolate and characterise blood-derived EVs in
CFS/ME. Blood samples were collected from 10 Spanish CFS/ME patients and 5 matched healthy
controls (HCs), and EVs were isolated from the serum using a polymer-based method. Their protein
cargo, size distribution and concentration were measured by Western blot and nanoparticle
tracking analysis. Furthermore, EVs were detected using a lateral flow immunoassay based on
biomarkers CD9 and CD63. We found that the amount of EV-enriched fraction was significantly
higher in CFS/ME subjects than in HCs (p = 0.007) and that EVs were significantly smaller in CFS/ME
patients (p = 0.014). Circulating EVs could be an emerging tool for biomedical research in CFS/ME.
These findings provide preliminary evidence that blood-derived EVs may distinguish CFS/ME
patients from HCs. This will allow offer new opportunities and also may open a new door to
identifying novel potential biomarkers and therapeutic approaches for the condition.
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Chronic Fatigue Syndrome (CFS), also known as Myalgic
Encephalomyelitis (ME), is a complex, multisystem and
metabolic-neuroinflammatory condition with genetic
predisposition of unknown etiology characterised by pro-
longed and disabling chronic fatigue, which worsens with
physical and cognitive exertion. CFS/ME may also be
accompanied by other cardinal symptoms that include
orthostatic intolerance, unrefreshing sleep, gastrointest-
inal discomfort, neuropsychological impairment, anxi-
ety/depression, chronic pain and post-exertional malaise
lasting more than 24 h. CFS/ME occurs more often in
women than in men and is less common among children
and adolescents. Currently, no established diagnostic
laboratory tests exist, nor are any FDA-approved drugs
available for treatment [1].
Over the past decade, many studies have been con-
ducted on Extracellular Vesicles (EVs) in the field of
biomedical research. EVs secretion and EV-mediated
pathways are known to be important players in a
variety of biological processes under physiological and
pathological conditions. EVs cargo from donor cells
may interact with recipient cells, making them poten-
tial intercellular mediators. In fact, several proteins
such as heat shock proteins, integrins and tetraspanins
can be found in all EVs [2,3]. Moreover, tetraspanins
CD9, CD63 and CD81 are commonly used as conven-
tional EV markers since they are enriched in their
membranes [3–5].
In addition, EVs may be altered in number and
composition in several conditions [6–9], and they
have emerging as potential biomarkers of diagnosis
and prognosis [10]. To date, there are no published
reports of EVs isolation and characterisation in CFS/
ME. As the pathomechanisms of CFS/ME described in
the literature [11], may promote EVs release, we pro-
posed to characterise circulating EVs in CFS/ME to
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assess their new potential as biomarkers for the
condition.
In this proof of concept study, we isolated human
serum-derived EVs from CFS/ME subjects and healthy
controls (HCs) in order to characterise them in terms
of size and concentration. We also analysed their com-
position using a lateral flow immunoassay (LFIA) sys-
tem optimised for rapid on-site detection.
Patients and methods
Ethics committee
The study was approved by the local Institutional
Review Board and Human Research Ethics
Committee of the Vall d’Hebron University Hospital
Institute. All participants provided written informed
consent prior to participation in the study.
Participants
A total of 10 potentially eligible Caucasian females with
CFS/ME (mean age ± SD; 46.3 ± 8.5 years) according to
the 1994 CDC/Fukuda definition [12] were recruited
from a single outpatient tertiary referral centre (CFS/
ME Unit, Vall d’Hebron University Hospital, Barcelona,
Spain). Five matched sedentary non-fatigued healthy
controls (HCs) (mean age ± SD; 44.2 ± 6.2 years) were
also included. Exclusion criteria were comorbid psy-
chiatric illness, endocrino-metabolic, haematological
and autoimmune disorders, CVD, pregnancy or breast-
feeding, drug abuse, smoking or symptoms of CFS/ME
that did not conform to the 1994 CDC/Fukuda
definition.
Sample collection and processing
Fresh blood samples were collected at the local site
between 8 and 9 a.m. after fasting for at least 12 h.
Blood samples were collected from antecubital vein by
venipuncture with a 21-gauge needle in a 10 ml BD
Vacutainer® Plus serum tube after discarding the first
millilitre. All tubes were kept upright and allowed to
clot for 30 min. Serum was separated after centrifuga-
tion at 1,500 x g for 15 min at RT within the first hour
(Heraeus Megafuge 16R centrifuge with a 75,003,629
rotor, Thermo Scientific, Madrid, Spain). All 1.5 ml
aliquots were snap-frozen in liquid nitrogen, and then
stored at −80ºC until further analysis. Frozen serum
aliquots in dry-ice from all participants were sent to
University of Oviedo (Asturias, Spain) for further iso-
lation and characterisation of EVs.
Isolation of EVs
EVs were purified using the ExoQuickTM precipitation
solution (System Biosciences) according to the manu-
facturer’s instructions. Briefly, 250 µl of serum from all
subjects were centrifuged at 3,200 x g for 15 min at RT
to remove platelets and cell debris and mixed with
ExoQuick Precipitation Solution. EVs were precipitated
by low speed centrifugation (1,500 x g) and resus-
pended in the appropriate buffer following the manu-
facturer’s instructions.
EVs characterisation
Protein quantification and western blot analysis
Protein concentration of the EV fractions was mea-
sured by bicinchoninic acid (BCA) assay kit (Thermo
Scientific, Waltham, MA, USA). The EV fractions
were homogenised with 1× RIPA buffer (25 mM
Tris pH 7.4, 150 mM NaCl, 1% NP-40, 1% Na-
Deoxycholate, 0.1% SDS) containing proteases and
phosphatases inhibitors. Equal volumes of each sam-
ple were mixed with reducing 1x Laemmli-buffer,
loaded and run on 12% SDS-PAGE gel under non-
reducing conditions. Proteins were transferred to
PVDF membrane (Amersham; GE Healthcare,
Munich, Germany). Membranes were blocked in 5%
non-fat dry milk using TBS containing 0.1% Tween-
20 (TBS-T) and then probed with polyclonal anti-
CD63 diluted 1:500 (Santa Cruz Biotech; Santa
Cruz, CA, USA) overnight at +4ºC with gently rock-
ing. Membranes were washed with TBS-T for 3 times
and 10 min each, and finally HRP-conjugated sec-
ondary antibodies diluted 1:2000 (Dako, Glostrup,
Denmark) were added for 1 h at room temperature.
Blots were developed using the ECL detection system
(GE Healthcare, Madrid, Spain).
Nanoparticle tracking analysis
Concentration and size distribution of the isolated EVs
were determined by NanoSight LM10 instrument
(Malvern, Worcestershire, UK) and nanoparticle track-
ing analysis (NTA) 3.1 software at NanoVex
Biotechnologies S.L (Madrid, Spain). Each EV fraction
was diluted between 1:1000 and 1:200,000 in 10 mM
HEPES pH 7.4 to achieve a particle concentration ran-
ging from 106 to 109 particles/ml. Three recordings were
performed at 25ºC for each sample. Zetasizer software
version 7.03 was used for data processing and analysis.
Lateral flow immunoassay
Detection of purified EVs from CFS/ME patients and
HCs by single-targeted LFIA was performed as
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previously described [13], using the following mono-
clonal antibodies: anti-CD9 (clone VJ1/20) and anti-
CD63 (clone Tea3/18) (both from Immunostep,
Madrid, Spain). Briefly, EV samples were homoge-
nised with the detection antibody conjugated to gold
nanoparticles (AuNP-anti-CD63). Anti-CD9 immo-
bilised on the strip was used as capture antibody.
Then the immunostrip was added and the samples
were allowed to run for 15 min. Unbound AuNP-
conjugated migrated further to be captured with an
anti-IgG antibody, and this was used as system func-
tional verification. The signal intensities were mea-
sured with the ESEQuant LR3 lateral flow strip
reader (Qiagen, Madrid, Spain). For more details
regarding the nanoparticle-antibody conjugation
and the preparation of the immunostrip, see the
studies previously published by Oliveira-Rodríguez
et al. [14,15].
Statistical analysis
All statistical data analyses were performed with the
freely available software R.3.1 (www.r-project.org).
Data were analysed by Mann–Whitney U test (non-
parametric test), and p < 0.05 was considered as statis-
tically significant.
Results and discussion
Determination of protein amount and detection of
CD63 in EV fractions
EVs were isolated from 250 μl of serum of 10 CFS/ME
patients and five matched-HCs. The amount of protein
in the EV fractions was determined (Figure 1(a)). We
found significantly higher protein content in CFS/ME
patients than in controls (mean ± SD, 65.49 ± 10.75 mg/
ml vs. 43.62 ± 5.10 mg/ml; p = 0.001, respectively). The
Bradford assay is commonly used to determine the
protein content of isolated EVs and to estimate the
amount of circulating EVs [13]. Moreover, analysis of
the EV protein content may differentiate between CFS/
ME individuals and controls. The content of EVs has
been reported to be higher in certain CNS disorders
[16], which may serve as a biomarker in the develop-
ment of new diagnostic tools for early stages of CFS/ME.
In our study, a significant abundance of blood-derived
EVs in CFS/ME subjects was shown by a 1.5-fold
increase on average compared to HCs.
We also determined the presence of the commonly
used marker CD63 in the purified EV fractions of CFS/
ME patients and healthy controls. In addition, since
our LFIA system for the detection of EVs uses anti-
CD63 as detection antibody, we checked that the levels
of this tetraspanin in our CFS/ME cohort were
Figure 1. (a) Box plot for the protein concentration of the EV fractions isolated in 10 CFS/ME patients and 5 healthy controls (HCs).
(b) Box plot for the measurement of CD63 levels by optical density (O.D.) in CFS/ME individuals (n = 10) and HCs (n = 5). (c)
Detection of CD63 (25 kDa) in EV fractions from CFS/ME patients and HCs by western blotting (left lane shows 26 kDa band
corresponding to the molecular weight marker).
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sufficient to use this approach. Equal volumes of each
sample were analysed by Western blot (Figure 1(b)).
Levels of CD63 were also higher in CFS/ME patients
than in the control group (Figure 1(c)), although the
difference did not reach statistical significance.
Characterization of EVs from CFS/ME patients and
healthy controls
Isolated EV fractions were further characterised for the
analysis of size distribution and concentration by NTA
(Figure 2(a)). The mean diameter measured in both
groups is shown in Figure 2(b). The population of par-
ticles was quite homogeneous in terms of size of circu-
lating EVs from CFS/ME patients (range 103–183 nm),
but EVs isolated from HCs were more heterogeneous,
with diameter sizes ranging from 140 to 271 nm. In fact,
EVs from the control group were significantly larger
than those from CFS/ME subjects (p = 0.014).
Regarding the concentration of the isolated EV frac-
tions, we found larger number of particles in CFS/ME
patients than in controls (1015 particles/ml vs. 4.88x1012
particles/ml; p = 0.007, respectively) (Figure 2(c)).
It is currently accepted that the size of EVs of
endocytic origin (commonly known as exosomes) is
typically in the range of 30–150 nm [5,17,18]. Our
results indicate that EV fractions from CFS/ME
patients may be rich in exosomes in comparison with
HCs, in whom we found larger diameters that may
correspond mostly to microvesicles. EVs are emerging
targets for biomedical research and these findings show
the first evidence that the number of circulating EVs
may distinguish between CFS/ME patients and healthy
controls.
Detection of EVs expressing tetraspanin CD9 by
LFIA
In the study of EV biology, their isolation is as challen-
ging as their detection. In this respect, LFIA provides a
powerful tool for low-cost on-site detection. In this
study, subsequent LFIA analysis was performed to
allow rapid detection of circulating EVs upon isolation
[19]. Anti-CD63 was used as detection antibody and
anti-CD9 as the capture antibody printed in the test
line, anti-IgG was used for the control line [14].
Figure 3(a) shows a representative example of the
results obtained with EV fractions isolated from a
CFS/ME patient and a healthy control subject. EV-
depleted serum was used as a negative control.
Unbound anti-CD63-AuNPs captured with anti-IgG
were used for system functional verification.
Figure 2. Characterization of isolated EVs by NTA. (a) Representative graph depicting the hydrodynamic size distribution profiles of
isolated EVs from a CFS/ME subject and an HC, measured by NTA. (b) Box plots for the diameter sizes and (c) particle concentration
of the EV fractions of study participants.
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Optical signal intensities were evaluated by reflectance
measurements. It is worth noting that only 1 µl of the
fractions was required to obtain a visible signal (red line)
and therefore to detect EVs. We found no significant
differences regarding the intensity of the CD9 signal on
EV-enriched fractions between CFS/ME patients and
HCs as shown in Figure 3(b). This implies questioning
the use of CD9 as a standard exosomal marker on CFS/
ME EVs; since the expression level of this tetraspanin
was not significantly differ between both groups.
The LFIA platform was used as an initial approach
and it is suitable for rapid detection of EVs, as previously
reported [13,16]; in addition, our LFIA system can be
further optimised or adapted to detect other biomarkers
of interest. Therefore, we consider it to be a good starting
point. Nevertheless, further studies with more CFS/ME
patients and healthy controls are needed to explore pos-
sible differences in circulating EVs regarding the pre-
sence of other tetraspanins or other EV-encapsulated
markers such as DNA, RNA species, lipids, proteins,
cytokines and metabolites among others.
Conclusions
This report is the first show that numbers of blood-
derived EVs are elevated in patients suffering from
CFS/ME, indicating their potential involvement in dis-
ease pathogenesis. This promising finding may not only
provide insights into the mechanisms involved in the
disease but also shows that EVs may be useful for early
diagnosis of illness. Moreover, isolation of circulating
EVs coupled to our prototype for their detection by
LFIA may constitute a powerful diagnostic tool, which
can be performed in a single step and in minutes. We
concluded that EVs may play a critical role in CFS/ME.
Studies with larger sample size, outcome measures and
different study designs (i.e. cross-sectional vs. longitu-
dinal cohorts) are now urgently needed. These studies
should stratify subgroups according to illness onset and
progression, and assess patients at baseline and follow-
ing induction of post-exertional malaise (PEM), using
the 2-day cardiopulmonary exercise test (CPET).
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Figure 3. Detection of serum isolated-EVs using anti-CD9 as
capture antibody and AuNP-anti-CD63 as detection probe. (a)
Representative immunostrip test obtained of HCs and CFS/ME
individuals. EV-depleted serum was used as negative control
(C-). Control line (Ct). Test line (CD9). (b) Box plots for the signal
intensities measured with the ESEQuant LR3 lateral flow strip
reader of study participants.
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